Janssen Receives CHMP Positive Opinion for Guselkumab Recommending Approval for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union

Pending approval, guselkumab will be the first biologic that selectively blocks interleukin (IL)-23 FOR MEDICAL AND TRADE MEDIA ONLY BEERSE, Belgium, Sept. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Janssen-Cilag International NV annou... Biopharmaceuticals, Dermatology, Regulatory Janssen-Cilag, Janssen, guselkumab, psoriasis

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2042975

Source: HSMN NewsFeed - September 15, 2017 Category: Pharmaceuticals Source Type: news